JP2013107903A5 - - Google Patents

Download PDF

Info

Publication number
JP2013107903A5
JP2013107903A5 JP2013045053A JP2013045053A JP2013107903A5 JP 2013107903 A5 JP2013107903 A5 JP 2013107903A5 JP 2013045053 A JP2013045053 A JP 2013045053A JP 2013045053 A JP2013045053 A JP 2013045053A JP 2013107903 A5 JP2013107903 A5 JP 2013107903A5
Authority
JP
Japan
Prior art keywords
bis
composition
phenylene
methylene
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013045053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013107903A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013107903A publication Critical patent/JP2013107903A/ja
Publication of JP2013107903A5 publication Critical patent/JP2013107903A5/ja
Pending legal-status Critical Current

Links

JP2013045053A 2005-08-19 2013-03-07 化学療法の強化方法 Pending JP2013107903A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70997805P 2005-08-19 2005-08-19
US60/709,978 2005-08-19
US73473605P 2005-11-08 2005-11-08
US60/734,736 2005-11-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008527219A Division JP2009504788A (ja) 2005-08-19 2006-08-21 化学療法の強化方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013169087A Division JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Publications (2)

Publication Number Publication Date
JP2013107903A JP2013107903A (ja) 2013-06-06
JP2013107903A5 true JP2013107903A5 (enExample) 2013-10-03

Family

ID=37758501

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008527219A Pending JP2009504788A (ja) 2005-08-19 2006-08-21 化学療法の強化方法
JP2013045053A Pending JP2013107903A (ja) 2005-08-19 2013-03-07 化学療法の強化方法
JP2013169087A Pending JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008527219A Pending JP2009504788A (ja) 2005-08-19 2006-08-21 化学療法の強化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013169087A Pending JP2013231086A (ja) 2005-08-19 2013-08-16 化学療法の強化方法

Country Status (9)

Country Link
US (1) US20070043012A1 (enExample)
EP (1) EP1951046B1 (enExample)
JP (3) JP2009504788A (enExample)
CN (1) CN101365336B (enExample)
AU (1) AU2006280945A1 (enExample)
BR (1) BRPI0615180A2 (enExample)
CA (1) CA2619828A1 (enExample)
IL (1) IL189599A0 (enExample)
WO (1) WO2007022523A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) * 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
EP3011961B1 (en) * 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
WO2008109076A1 (en) * 2007-03-02 2008-09-12 Oxigene, Inc. Methods for enhancing the efficacy of vascular disrupting agents
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
US20110207814A1 (en) * 2009-12-23 2011-08-25 Pranela Rameshwar Combination Therapy for Breast Cancer Treatment
SG188220A1 (en) * 2010-09-09 2013-04-30 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CN105163749B (zh) 2013-03-24 2018-03-27 拜欧肯治疗有限公司 治疗骨髓性白血病的方法
EP3062809B1 (en) 2013-10-31 2020-07-08 Biokine Therapeutics Ltd. A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation
JP2017508005A (ja) * 2014-02-19 2017-03-23 マイクロコンスタンツ チャイナ インク ケモカイン受容体アンタゴニストおよびその併用療法
KR101759688B1 (ko) * 2015-01-16 2017-07-20 서울대학교산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
WO2016114634A2 (ko) * 2015-01-16 2016-07-21 서울대학교 산학협력단 사이클램 유도체 화합물 및 이의 약학적 용도
MX2017013668A (es) * 2015-04-25 2018-07-06 Massachusetts Gen Hospital Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
AU2016324303A1 (en) * 2015-09-18 2018-04-26 The General Hospital Corporation Dba Massachusetts General Hospital Modified T-cells having anti-fugetactic properties and uses thereof
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN109069426B (zh) * 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
CA3066778A1 (en) * 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020065647A1 (en) 2018-09-25 2020-04-02 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
TWI781469B (zh) * 2020-10-27 2022-10-21 行政院原子能委員會核能研究所 複合物、造影劑及治療與cxcr4接受體相關疾病的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005204A (en) * 1973-03-23 1977-01-25 Burroughs Wellcome Co. Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP1244648B1 (en) * 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
KR20030034184A (ko) 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
RU2289581C2 (ru) 2000-09-15 2006-12-20 Анормед, Инк. Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
CA2431611A1 (en) 2001-01-23 2002-08-01 P&G-Clairol, Inc. Primary intermediates for oxidative coloration of hair
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1608318A4 (en) 2003-03-27 2009-07-29 Univ Emory CXCR4 ANTAGONISTS AND METHOD OF USE
US20040202935A1 (en) 2003-04-08 2004-10-14 Jeremy Barker Cathode active material with increased alkali/metal content and method of making same
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
AU2006340074A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration

Similar Documents

Publication Publication Date Title
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
JP2013107903A (ja) 化学療法の強化方法
JP2022520061A5 (enExample)
JP2020097577A5 (enExample)
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP2013507439A5 (enExample)
JP2019511565A (ja) ツカレゾールまたはそのアナログを含む組成物
JP2016534142A5 (enExample)
US20220047507A1 (en) Melflufen dosage regimens for cancer
JP2012502915A5 (enExample)
WO2011159100A2 (ko) 항암 활성을 나타내는 약제학적 조성물
JP2014521641A5 (enExample)
JP2016515550A5 (enExample)
JP2014148552A5 (enExample)
WO2007108272A1 (ja) 癌治療用キットおよび癌治療用医薬組成物
SI2847204T1 (en) Sterol derivatives and their use for the treatment of diseases involving the transformation of astrocytic cells or the treatment of malignant haemopathies
JP2016501208A5 (enExample)
HRP20191322T1 (hr) Antitumorska kombinacija koja sadži kabazitaksel i cisplatin
RU2017125150A (ru) Фармацевтическая композиция для лечения или создания условий ремиссии у пожилого пациента с раком или у пациента на терминальной стадии рака
CN103417977A (zh) 叶酸受体α亚型高效介导的靶向投药系统
KR20090103899A (ko) 백혈병을 치료하기 위한 신규한 치료 용도
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
EP2826482A1 (en) Novel antitumor agent comprising combination of three agents
JP2019525924A5 (enExample)